If you are interested in the national debate about how providers, payers, pharmaceutical companies and startups are working to improve adherence and outcomes through patient engagement, here a 10 people to follow on Twitter.
Lisa Maki (@LisaMMaki) is the CEO of PokitDok, a company focusing on providing price transparency in healthcare.
Dr. Ivor Horn (@DrIvorHorn) is an associate professor of Pediatrics at Children’s National Medical Center in Washington, DC.
Peter L. Levin (@pllevin) is the senior adviser to the Secretary and Chief Technology Officer at the U.S. Department of Veterans Affairs.
Albert Shar (@alshar) is the managing principal at QERT.
Dr. Joseph Kvedar (@jkvedar) is the director for the Center for Connected Health and an associate professor of Harvard Medical School.
Dr. Harold Freeman (@HPFreemanPNI) is the founder and CEO of the Harold P Freeman Patient Navigation Institute.
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Lygeia Ricciardi (@Lygeia) is the director for the Office of Consumer eHealth at the ONC.
Sarah Kucharski (@FMDChat) is the CEO, chairman and founder of FMD Chat, a network that supports those affected by fibromuscular dysplasia by connecting patients, family members and providers via social media.
Ash Damle (@AshDamle) is the CEO of health analytics platform MEDgle.com.
Dr. Geeta Nayyar (@GNayyar) is a physician and the Chief Medical Information Officer for AT&T.
